Literature DB >> 28574967

Dolutegravir and weight gain: an unexpected bothering side effect?

Amélie Menard1, Line Meddeb, Herve Tissot-Dupont, Isabelle Ravaux, Catherine Dhiver, Saadia Mokhtari, Christelle Tomei, Philippe Brouqui, Philippe Colson, Andreas Stein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28574967     DOI： 10.1097/QAD.0000000000001495

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  48 in total

Review 1.  Initial Antiretroviral Therapy in an Integrase Inhibitor Era: Can We Do Better?

Authors:  Sean G Kelly; Mary Clare Masters; Babafemi O Taiwo
Journal:  Infect Dis Clin North Am       Date:  2019-06-22       Impact factor: 5.982

Review 2.  Factors Associated With Insulin Resistance in Adults With HIV Receiving Contemporary Antiretroviral Therapy: a Brief Update.

Authors:  Todd Hulgan
Journal:  Curr HIV/AIDS Rep       Date:  2018-06       Impact factor: 5.071

Review 3.  Obesity and Weight Gain in Persons with HIV.

Authors:  Samuel S Bailin; Curtis L Gabriel; Celestine N Wanjalla; John R Koethe
Journal:  Curr HIV/AIDS Rep       Date:  2020-04       Impact factor: 5.071

4.  Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.

Authors:  Kassem Bourgi; Peter F Rebeiro; Megan Turner; Jessica L Castilho; Todd Hulgan; Stephen P Raffanti; John R Koethe; Timothy R Sterling
Journal:  Clin Infect Dis       Date:  2020-03-17       Impact factor: 9.079

Review 5.  Prevention of cardiovascular disease among people living with HIV in sub-Saharan Africa.

Authors:  Samson Okello; Abdallah Amir; Gerald S Bloomfield; Katie Kentoffio; Henry M Lugobe; Zahra Reynolds; Itai M Magodoro; Crystal M North; Emmy Okello; Robert Peck; Mark J Siedner
Journal:  Prog Cardiovasc Dis       Date:  2020-02-05       Impact factor: 8.194

6.  Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors.

Authors:  David R Bakal; Lara E Coelho; Paula M Luz; Jesse L Clark; Raquel B De Boni; Sandra W Cardoso; Valdilea G Veloso; Jordan E Lake; Beatriz Grinsztejn
Journal:  J Antimicrob Chemother       Date:  2018-08-01       Impact factor: 5.790

7.  Weight gain in antiretroviral therapy-naive HIV-1-infected patients starting a regimen including an integrase strand transfer inhibitor or darunavir/ritonavir.

Authors:  Leonardo Calza; Vincenzo Colangeli; Marco Borderi; Isabella Bon; Aurora Borioni; Francesca Volpato; Maria Carla Re; Pierluigi Viale
Journal:  Infection       Date:  2019-11-12       Impact factor: 3.553

8.  Insights Into the Pathophysiology of Liver Disease in HCV/HIV: Does it End With HCV Cure?

Authors:  Andre J Jeyarajan; Raymond T Chung
Journal:  J Infect Dis       Date:  2020-11-27       Impact factor: 5.226

9.  HIV and the liver.

Authors:  Kenneth E Sherman; Marion G Peters; David L Thomas
Journal:  Top Antivir Med       Date:  2019-09

10.  Weight Gain Associated With Integrase Stand Transfer Inhibitor Use in Women.

Authors:  Anne Marie Kerchberger; Anandi N Sheth; Christine D Angert; C Christina Mehta; Nathan A Summers; Ighovwerha Ofotokun; Deborah Gustafson; Sheri D Weiser; Anjali Sharma; Adaora A Adimora; Audrey L French; Michael Augenbraun; Jennifer Cocohoba; Seble Kassaye; Hector Bolivar; Usha Govindarajulu; Deborah Konkle-Parker; Elizabeth T Golub; Cecile D Lahiri
Journal:  Clin Infect Dis       Date:  2020-07-27       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.